Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

NCT02322853 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT02322853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02322853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Lead sponsor
Centre Francois Baclesse
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2015
Completion date
April 30, 2017
Enrollment
8 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, postmenopausal